购物车
  • 全部删除
  • TargetMol
    您的购物车当前为空

Cipemastat

Rating icon 还可以
产品编号 T10817Cas号 190648-49-8
别名 Ro 32-3555

Cipemastat is a competitive inhibitor of human collagenases 1, 2, and 3 (Kis: 3.0, 4.4, and 3.4 nM).

Cipemastat

Cipemastat

Rating icon 还可以
产品编号 T10817 别名 Ro 32-3555Cas号 190648-49-8

Cipemastat is a competitive inhibitor of human collagenases 1, 2, and 3 (Kis: 3.0, 4.4, and 3.4 nM).

规格价格库存数量
5 mg¥ 3,7505日内发货
50 mg¥ 18,6005日内发货
100 mg¥ 25,5005日内发货
大包装 & 定制
加入购物车
实验操作小课堂
查看更多
联系我们获取更多批次信息
资源下载
TargetMol 的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。

产品介绍

生物活性
产品描述
Cipemastat is a competitive inhibitor of human collagenases 1, 2, and 3 (Kis: 3.0, 4.4, and 3.4 nM).
靶点活性
Gelatinase B:59.1 nM (ki), Gelatinase A:154 nM (ki), Collagenases 1:3.0 nM (ki), MMP3:527 nM (ki), Collagenases 3:3.4 nM (ki), Collagenases 2:4.4 nM (ki)
体外活性
Cipemastat (Ro 32-3555) is also a potent inhibitor of rat collagenase (IC50: 44.7 nM). In vitro cartilage degradation ± inhibited IL-1a induced cartilage degradation in vitro in a concentration-dependent manner (IC50: 60 nM). The inhibition is not mediated by a cytotoxic action on explant chondrocytes. Cipemastat, at all concentrations tested, fails to modify glucose utilization when compared to explants cultured in the presence of IL-La alone.
体内活性
The amount of hydroxyproline in non-implanted cartilage is 119.3 nM/mg and this decreases in cartilages implanted in vehicle-dosed animals to 53.6 nM/mg over a fourteen-day period. Animals administered Cipemastat orally at doses of 2.5, 5, 10, and 25 mg/kg showed statistically increased levels of implanted cartilage hydroxyproline. Fourteen days after the second challenge injection of P. acnes, the area of cartilage most consistently affected by pannus is the lateral femoral condyle, which is the area analyzed. In arthritic animals, there is a significant decrease to a mean area of 0.086±0.01 mm2 (n=10). In non-arthritic animals, the mean cartilage area is 0.17±0.02 mm2 (n=5). The group of animals dosed with Cipemastat (50 mg/kg, p.o.) show a significantly greater area of cartilage with a mean value of 0.126±0.012 mm2 (n=9). The pannus area in vehicle-dosed animals is 0.099±0.017 mm2 and in Cipemastat dosed animals 0.102 mm2. Adjuvant arthritis injection of adjuvant-induced two phases of swelling of the injected paw in vehicle-dosed rats. The primary swelling phase occurred between days 0 to 5 and induced an increase in paw volume of 1.9±0.1 mL; the second phase occurs between days 9 to 14 and there was an increase in paw swelling of 0.98±0.08 mL. The group of animals dosed with dexamethasone (0.1 mg/kg) shows a significant reduction in both primary (0.2±0.03 mL) and secondary inflammation (0.07±0.08 mL) paw swelling as well as total inhibition of the lesion score.
别名Ro 32-3555
化学信息
分子量436.55
分子式C22H36N4O5
CAS No.190648-49-8
密度1.205 g/cm3 (Predicted)
储存&溶解度
存储Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

计算器

  • 摩尔浓度 计算器
  • 稀释 计算器
  • 配液 计算器
  • 分子量 计算器

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
TargetMol | Animal experiments比如您的给药剂量是 10 mg/kg ,每只动物体重 20 g ,给药体积 100 μLTargetMol | Animal experiments 一共给药动物 10 只 ,您使用的配方为 5% TargetMol | reagent DMSO+ 30%PEG300+ 5%Tween 80 + 60% ddH2O. 那么您的工作液浓度为 2 mg/mL
母液配置方法: 2 mg 药物溶于 50 μLDMSOTargetMol | reagent ( 母液浓度为 40 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:50μLDMSOTargetMol | reagent 母液,添加 300 μLPEG300TargetMol | reagent 混匀澄清,再加 50μLTween 80, 混匀澄清,再加 600μLddH2OTargetMol | reagent 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

1 请输入动物实验的基本信息
mg/kg
g
μL
2 请输入动物体内配方组成,不同的产品配方组成不同,如有配方需求,可先联系我们提供正确的体内配方。
% DMSO
%
%Tween 80
%ddH2O

剂量转换

对于不同动物的给药剂量换算,您也可以参考 更多

关键词

评论列表

4个月前
5.0
Rating icon 很棒

评论内容

Related Tags: buy Cipemastat | purchase Cipemastat | Cipemastat cost | order Cipemastat | Cipemastat chemical structure | Cipemastat in vivo | Cipemastat in vitro | Cipemastat formula | Cipemastat molecular weight